Table 1 Study cohort characteristics
|  | CD4 < 200 (N = 17) | CD4 > 200 (N = 17) | P value |
|---|---|---|---|
Mean age (years) | 50 ± 9 | 47 ± 7 | 0.2619 |
Weight (kg) | 54.71 ± 9.71 | 58.18 ± 8.63 | 0.1895 |
BMI (kg/m2) | 21.19 ± 3.52 | 21.69 ± 2.92 | 0.4691 |
Time on ART (years) | 7 ± 3 | 9 ± 2 | 0.0951 |
Gender, N (%) | |||
 Male | 7 (41.2) | 8 (47.1) | > 0.9999 |
 Female | 10 (50.0) | 9 (52.9) | |
Ethnicity, N (%) | |||
 Han | 4 (23.5) | 4 (23.5) | > 0.9999 |
 Other minorities | 13 (58.8) | 13 (76.5) | |
Acquisition of HIV, N (%) | |||
 Injection drug use | 3 (17.6) | 1 (5.9) | 0.7309 |
 Sexual route | 12 (70.6) | 14 (82.3) | |
 Unknown | 2 (11.8) | 2 (11.8) | |
T cells (cells/μL) | |||
 CD4+ T cell counts before ART | 159 ± 143 | 210 ± 149 | 0.1425 |
 CD3+ T cell counts | 642 ± 263 | 764 ± 178 | 0.0518 |
 CD4+ T cell counts | 149 ± 38 | 266 ± 57 | < 0.0001* |
 CD8+ T cell counts | 448 ± 233 | 454 ± 171 | 0.4902 |
 CD4/CD8 ratio | 0.40 ± 0.20 | 0.72 ± 0.45 | 0.0033* |
 Nadir CD4+ T cell counts | 144 ± 37 | 239 ± 36 | < 0.0001* |
ART regimens, N (%) | |||
 NRTI + NNRTI | 13 (76.5) | 17 (100) | 0.1026 |
 NRTI + PI | 4 (23.5) | 0 (0) | |
 3TC + AZT + EFV | 4 (23.5) | 5 (29.4) | 0.1404 |
 3TC + AZT + NVP | 3 (17.6) | 6 (35.3) | |
 3TC + TDF + EFV | 5 (29.4) | 5 (29.4) | |
 3TC + AZT + LPV | 2 (11.8) | 0 (0) | |
 3TC + TDF + NVP | 1 (5.9) | 1 (5.9) | |
 TDF + AZT + LPV | 1 (5.9) | 0 (0) | |
 3TC + LPV | 1 (5.9) | 0 (0) | |